Evrim Çelebi

Evrim Çelebi

Auto-generated profile, based on publicly available information

Evrim Çelebi

Basaksehir Cam and Sakura City Hospital, Turkey

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2022 in Revista da Associação Médica Brasileira
Verified
Journal Article
Open access
CYCüneyd Yavaş
Cüneyd Yavaş
CÜCemal Ün
Cemal Ün
EÇEvrim Çelebi
Evrim Çelebi
AGAlper Gezdirici
Alper Gezdirici
MDMustafa Dogan
Mustafa Dogan
NONehir Ozdemir Ozgenturk
Nehir Ozdemir Ozgenturk
Chronic kidney disease (CKD) remains one of the major common health problems, and the number of people affected by the disease is progressively increasing in Turkey and worldwide. This study aimed to investigate molecular defects in Alport syndrome (AS) and other genes in patients with clinically suspected CKD using whole-exome sequencing (WES). Patients with clinical suspicion of CKD were included in the study. Molecular genetic analyses were performed on genomic DNA by using WES. A total of 15 with 5 different pathogenic or likely pathogenic variants were identified in CKD patients, with a diagnostic rate of 30%. Eight variants of uncertain significance were also detected. In this study, 10 variants were described for the first time. As a result, we detected variants associated with CKD in our study population and found AS as the most common CKD after other related kidney diseases. Our results suggest that in heterogeneous diseases such as CKD, WES analysis enables accurate identification of underlying molecular defects promptly. Although CKD accounts for 10–14% of all renal dysfunction, molecular genetic diagnosis is necessary for optimal long-term treatment, prognosis, and effective genetic counseling.